文献速递妇科

美克洛嗪改善诱导性子宫腺肌症小鼠的子宫内膜修复并减少模拟月经出血量

Meclizine improves endometrial repair and reduces simulated menstrual bleeding in mice with induced adenomyosis.
PubMed 文献 · Am J Obstet Gynecol · 2024-02-16

本研究在36只诱导性子宫腺肌症C57BL/6雌鼠中建立模拟月经模型,随机分为低剂量美克洛嗪组、高剂量美克洛嗪组和对照组,发现美克洛嗪剂量依赖性加速子宫内膜修复、减少月经出血量,并降低子宫内膜纤维化程度、抑制病灶进展。

要点

  • 在诱导性子宫腺肌症小鼠中,美克洛嗪剂量依赖性加速子宫内膜修复并减少月经出血量。
  • 美克洛嗪提高子宫内膜Hk2和Pfkfb3免疫表达,但不提高Glut1或Pkm2表达。
  • 美克洛嗪降低子宫内膜纤维化程度,并剂量依赖性抑制病灶进展。

核心结论

  • 糖酵解可能是子宫腺肌症所致月经过多的有前景治疗靶点,美克洛嗪可能作为不加重疾病的非激素治疗选择。

研究设计与样本

  • 研究为动物实验,使用36只C57BL/6雌鼠通过子宫内膜-肌层界面破坏诱导子宫腺肌症,诱导3个月后随机分为低剂量美克洛嗪组、高剂量美克洛嗪组和对照组。
  • 美克洛嗪或溶媒治疗于模拟月经操作前不久开始,至孕酮撤退前结束。
  • 通过定量失血量及子宫组织学评估子宫内膜修复分级,并用Masson三色染色评估异位和正位子宫内膜纤维化程度。

主要发现

  • 在诱导性子宫腺肌症小鼠中,美克洛嗪剂量依赖性加速子宫内膜修复并减少月经出血量。
  • 美克洛嗪提高子宫内膜Hk2和Pfkfb3的免疫表达,但不提高Glut1或Pkm2的表达。
  • 美克洛嗪给药后子宫内膜纤维化程度降低,并伴随病灶进展抑制,表现为纤维化程度(病灶进展的替代指标)的剂量依赖性降低。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adenomyosis is one of the structural causes of abnormal uterine bleeding, which often presents as heavy menstrual bleeding. Mostly because of the poor understanding of its pathophysiology, medical management of adenomyosis-induced heavy menstrual bleeding is still a challenge. We have previously reported that glycolysis is crucial to endometrial repair following menstruation and that suppressed glycolysis can cause heavy menstrual bleeding. OBJECTIVE: This study aimed to test the hypothesis that meclizine, a drug with an excellent safety profile, alleviates heavy menstrual bleeding in mice with induced adenomyosis using a simulated menstruation model. STUDY DESIGN: Adenomyosis was induced in 36 female C57BL/6 mice using endometrial-myometrial interface disruption. Three months after induction, the mice were randomly divided into the following 3 groups: low-dose meclizine, high-dose meclizine, and controls. Treatment with meclizine or vehicle started shortly before the simulated menstruation procedure and ended before progesterone withdrawal. The amount of blood loss was quantified and uterine tissue was harvested for histologic evaluation of the grade of endometrial repair. We performed immunohistochemistry analysis of 4 proteins critically involved in glycolysis: Glut1 (glucose transporter 1), Hk2 (hexokinase 2), Pfkfb3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3), and Pkm2 (pyruvate kinase M2). The extent of tissue fibrosis in both ectopic and eutopic endometria was evaluated using Masson trichrome staining. RESULTS: In mice with induced adenomyosis, meclizine accelerated endometrial repair in a dose-dependent manner and reduced the amount of menstrual bleeding. Meclizine administration raised endometrial immunoexpression of Hk2 and Pfkfb3 but not of Glut1 or Pkm2. The extent of endometrial fibrosis was reduced following the meclizine administration. Remarkably, these favorable changes were accompanied by the suppression of lesional progression, as evidenced by the dose-dependent reduction in the extent of fibrosis (a surrogate for lesional progression). CONCLUSION: These encouraging results, taken together, suggest that glycolysis may be a promising therapeutic target and that meclizine may hold therapeutic potential as a nonhormonal treatment for adenomyosis-induced heavy menstrual bleeding without exacerbating the disease.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Mao C, Liu X, Guo SW, et al. Meclizine improves endometrial repair and reduces simulated menstrual bleeding in mice with induced adenomyosis. Am J Obstet Gynecol. 2024. PMID: 38367751. doi:10.1016/j.ajog.2024.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。